Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early phase 2 study of KSP-0243 in mild to moderate active ulcerative colitis
jRCT2031220717Phase 2Completed
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing KSP-0243 with Placebo (2 arms). Primary endpoint: Clinical response rate at Week 8 (modified Mayo score). Started Mar 2023; status: completed.
02
Drugs
KSP-0243
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2031220717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220717.